Drugs / ZN-e4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03446417 | Apr 2018 → Jan 2022 | non-small cell lung carcinoma | Zeno Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZN-e4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03446417 ↗ |
| Known as | KP-673 | “A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of ZN-e4 (KP-673) in Patients With Advanced Non-Small...” NCT03446417 ↗ |
| Route | Oral | “ZN-e4 administered orally” NCT03446417 ↗ |